SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-034323
Filing Date
2021-06-24
Accepted
2021-06-24 17:20:31
Documents
12
Period of Report
2021-06-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K 062421 ntla-8k_20210623.htm   iXBRL 8-K 68838
  Complete submission text file 0001564590-21-034323.txt   199200

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210623.xsd EX-101.SCH 5768
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210623_lab.xml EX-101.LAB 19475
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210623_pre.xml EX-101.PRE 11626
5 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20210623_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 211043787
SIC: 2835 In Vitro & In Vivo Diagnostic Substances